Phenomenex to Present Four Workshops at Pittcon 2013
News Dec 17, 2012
“Survey of Recent Advances in Protein Analysis” will be presented on Monday, March 18 at 8:00 a.m. in Room 1268. Speakers include industry experts from Amgen, Genentech, AB SCIEX and Phenomenex. Panelists will discuss current challenges and assay requirements as well as how they are integrating new technologies in chromatography and mass spectrometry for faster and more accurate protein analysis.
“Emerging Environmental Contaminants: Methodologies and Practices for Meeting New Performance Requirements” will be presented on Wednesday, March 20 at 8:00 a.m. in Room 1680. Scheduled panelists are from the EPA, TestAmerica, Horizon Technology, Phenova Certified Reference Materials and Phenomenex. Topics will include new testing requirements as well as information on how to achieve the highest efficiencies plus insight on the latest instrumentation in LC/MS/MS, automated sample preparation and GC/HRMS. This workshop will also cover proficiency testing and ways to optimize methods to maintain accreditation.
“New Advances in the Analysis of Oligonucleotide Therapeutics” will be presented on Wednesday, March 20 at 2:00 p.m. in Room 1268. Panelists will include experts from Merck, Novatia, AB SCIEX and Phenomenex. In this workshop, researchers from the growing field of therapeutic product development will discuss new analytical methods as well as increasing demands for the identification and quantitation of low-level genotoxic impurities from biological fluids.
“The Present and Future of Core-Shell Column Technology” will be presented on Thursday, March 21 at 8:00 a.m. in Room 2300. The panel will include experts from The Pennsylvania State University, Abbot Laboratories, Merck, Agilent, Advanced Materials Technology and Phenomenex. In this session industry experts will discuss the benefits they are realizing from using core-shell column technology in their laboratories. The workshop will also cover the latest methods and techniques that enable researchers to get the most from core-shell technology.
Phenomenex, celebrating its 30th anniversary in 2012, is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being.
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.